- olaparib2017 | First Faculty of Medicine
- Olaparib - the first PARP inhibitor in the treatment of malignant tumors2015 | First Faculty of Medicine
- Olaparib combined with chemotherapy for recurrent platinum - sensitive ovarian cancer : a randomised phase 2trial2015 | Publication without faculty affiliation
- Platinum-sensitive recurrent ovarian cancer and olaparib maintenance treatment - case report2019 | First Faculty of Medicine
- Olaparib as a maintenance therapy in newly diagnosed patients with ovarian cancer - SOLO1 study results2022 | Third Faculty of Medicine
- Benefit of olaparib in the treatment of ovarian cancer – clinical practice2023 | Third Faculty of Medicine
- PARP inhibitor olaparib great benefit for a defined group of patients with BRCA positive ovarian cancer2019 | Faculty of Medicine in Pilsen
- PARP inhibitor olaparib and anti-VEGF bevacizumab - targeted treatment and efforts to improve the outcome of patients with advanced tuboovarian cancer2020 | Faculty of Medicine in Pilsen
- Olaparib Synergizes the Anticancer Activity of Daunorubicin via Interaction with AKR1C32020 | Faculty of Pharmacy in Hradec Králové
- Olaparib2015 | Third Faculty of Medicine
- PARP inhibitors in treating metastatic castration-resistant prostate cancer2023 | First Faculty of Medicine
- Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis2022 | First Faculty of Medicine
- Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial2023 | First Faculty of Medicine
- Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment2020 | Publication without faculty affiliation
- Léčba platina-senzitivního recidivujícího karcinomu vaječníků s užitím inhibitoru PARP olaparibu2018 | First Faculty of Medicine
- Olaparib v léčbě recidivujícího karcinomu ovaria2019 | First Faculty of Medicine
- Nové možnosti léčby pacientek s mutacemi genů BRCA1/2 a karcinomem ovarií2017 | First Faculty of Medicine
- Promising treatment options of triple negative breast cancer2017 | First Faculty of Medicine, Central Library of Charles University
- Cílená léčba karcinomu ovaria2016 | First Faculty of Medicine
- Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial2015 | First Faculty of Medicine
- Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial2020 | First Faculty of Medicine
- WIP1 Promotes Homologous Recombination and Modulates Sensitivity to PARP Inhibitors2019 | Central Library of Charles University
- PARP inhibitors in ovarian cancer FOREWORD2015 | First Faculty of Medicine
- Inhibitory PARP - nová naděje pro pacientky s epiteliálním karcinomem ovaria2019 | Faculty of Medicine in Hradec Králové
- Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial2022 | First Faculty of Medicine
- News in the treatment of small cell lung cancer2022 | Faculty of Medicine in Pilsen
- AGO-OVAR 28/ENGOT-ov57. Niraparib alone versus niraparib in combination with bevacizumab in patients with carboplatin-taxane-based chemotherapy in advanced ovarian cancer: a multicenter randomized phase III trial2023 | First Faculty of Medicine